[
  {
    "ts": null,
    "headline": "How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created",
    "summary": "How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created",
    "url": "https://finnhub.io/api/news?id=67b35a900999d1c098ae1d597d7173c0a7ecb8b6a929a291229c163297fb6aa6",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748466000,
      "headline": "How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created",
      "id": 134812992,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created",
      "url": "https://finnhub.io/api/news?id=67b35a900999d1c098ae1d597d7173c0a7ecb8b6a929a291229c163297fb6aa6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer",
    "summary": "LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.",
    "url": "https://finnhub.io/api/news?id=eda5db9e5fa0556ae3e353ed40ba2771cf60688b886c80d1b33c7edbc486d1d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748446020,
      "headline": "Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer",
      "id": 134755777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.",
      "url": "https://finnhub.io/api/news?id=eda5db9e5fa0556ae3e353ed40ba2771cf60688b886c80d1b33c7edbc486d1d8"
    }
  },
  {
    "ts": null,
    "headline": "New Eli Lilly acquisition to progress potential next-generation pain treatment",
    "summary": "Eli Lilly and Company has agreed to acquire the biotech SiteOne Therapeutics, Inc. Shareholders of SiteOne will be eligible for a total of $1.0 billion in cash. The deal includes the ...",
    "url": "https://finnhub.io/api/news?id=f9ed1712098098f192668cb79a543961ea2912197d49838686173103b1c91c23",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748442666,
      "headline": "New Eli Lilly acquisition to progress potential next-generation pain treatment",
      "id": 134752943,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company has agreed to acquire the biotech SiteOne Therapeutics, Inc. Shareholders of SiteOne will be eligible for a total of $1.0 billion in cash. The deal includes the ...",
      "url": "https://finnhub.io/api/news?id=f9ed1712098098f192668cb79a543961ea2912197d49838686173103b1c91c23"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?",
    "summary": "Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.",
    "url": "https://finnhub.io/api/news?id=e99d9ef03056cbdd5328ef9e962005b9f0fbe23106571652a8668e960b93fb03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748438520,
      "headline": "Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?",
      "id": 134743413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.",
      "url": "https://finnhub.io/api/news?id=e99d9ef03056cbdd5328ef9e962005b9f0fbe23106571652a8668e960b93fb03"
    }
  }
]